A method for treating a mitochondrial complex I deficiency, the method comprising administering to an eye containing an inner plexiform layer and a ganglion cell layer of a patient having a mitochondrial complex I deficiency an amount of a caspase-9 signaling pathway inhibitor comprising XBIR3 conjugated to a cell-penetrating peptide effective to treat the mitochondrial complex I deficiency by decreasing the amount of 4-Hydroxynonenal (4-HNE) in the inner plexiform layer of the eye of the patient by more than 5%, reducing retinal thinning by at least 5%, decreasing the amount of cl-Casp-9 in the inner plexiform layer of the eye of the patient by more than 5%, or decreasing the rate of ganglion cell death in the ganglion cell layer as measured by an improvement of 5% minimum contrast detected as measured by contrast sensitivity testing.